Abstract: In order to detect a faulty error correcting unit (2) in an embedded system, wherein the error correcting unit (2) receives output data from a data source (20) and determines, whether the received data are incorrect, and wherein if the received data are incorrect, the error correcting unit (2) is expected to correct at least one error within the received data, output the corrected data and manipulate an error vector (4), a method and a system (Ia) are suggested that enable to compare the output data of the error correcting unit (2) with at least one reference data, wherein the at least one reference data originate at least indirectly from the data source (20). Both, the error vector (4) and the result of the comparison are input to a plausibility test in order to decide, whether the error correcting unit (2) is faulty. According to the result of the plausibility test, a failure vector (7) is manipulated in order to indicate whether a failure in the error correcting unit (2) is detected.

Abstract: In order to detect a faulty error correcting unit (2) in an embedded system, wherein the error correcting unit (2) receives output data from a data source (20) and determines, whether the received data are incorrect, and wherein if the received data are incorrect, the error correcting unit (2) is expected to correct at least one error within the received data, output the corrected data and manipulate an error vector (4), a method and a system (Ia) are suggested that enable to compare the output data of the error correcting unit (2) with at least one reference data, wherein the at least one reference data originate at least indirectly from the data source (20). Both, the error vector (4) and the result of the comparison are input to a plausibility test in order to decide, whether the error correcting unit (2) is faulty. According to the result of the plausibility test, a failure vector (7) is manipulated in order to indicate whether a failure in the error correcting unit (2) is detected.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

Abstract: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with an antidiabetic and an anticonvulsant.

Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.